Código QR (código de barras bidimensional)

Fixed-combination halobetasol propionate and tazarotene topical lotion decreases TNF-α and IL-17A levels in psoriatic lesions

Objective Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for the treatment of plaque psoriasis in adults, with a demonstrated efficacy and safety profile in phase 3 trials. This study examined the effect of HP/TAZ on the reduction of tumor necros...

תיאור מלא

שמור ב:
Principais autores: Zoe Diana Draelos, Matthew M. Draelos, Tina Lin, Abby Jacobson
פורמט: Artigo
שפה:Inglês
יצא לאור: Taylor & Francis Group 2023-12-01
סדרה:Journal of Dermatological Treatment
נושאים:
plaque psoriasis
inflammation
il-17a
tnf-α
גישה מקוונת:http://dx.doi.org/10.1080/09546634.2023.2245081
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים